

Focus on Managing Patients with Moderate-to-Severe Plaque Psoriasis

References

1. Alexis AF, Blackcloud P. Psoriasis in skin of color: Epidemiology, genetics, clinical presentation, and treatment nuances. *J Clin Aesth Derm*. 2014;7(11):16-24.
2. Nijsten T, Looman CN, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. *Arch Dermatol*. 2007;143(9):1113-1121.
3. Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. *Am J Prev Med*. 2014;47(1):37-45.
4. Queiro R, Tejon P, Alonso S, Coto P. Age at disease onset: a key factor for understanding psoriatic disease. *Rheumatology* (Oxford, England). 2014;53(7):1178-1185.
5. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. *J Invest Dermatol*. 2013;133(2):377-385.
6. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. *Nutr Diabetes*. 2012;2:e54.
7. Kumar S, Han J, Li T, Qureshi AA. Obesity, waist circumference, weight change and the risk of psoriasis in US women. *JEADV*. 2013;27(10):1293-1298.
8. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. *Arch Intern Med*. 2007;167(15):1670-1675.
9. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. *Br J Dermatol*. 2007;157(4):649-655.
10. Kivelevitch D, Schussler JM, Menter A. Coronary plaque characterization in psoriasis. *Circulation*. 2017; 136 (3); 277-280.
11. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. *J Am Acad Dermatol*. 2008;58(6):1031-1042.
12. Nguyen T, Wu JJ. Relationship between tumor necrosis factor-alpha inhibitors and cardiovascular disease in psoriasis: a review. *Perm J*. 2014;18(1):49-54.
13. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Implications for management. *J Am Acad Dermatol*. 2017;76(3):393-403.
14. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. *PLOS One*. 2012;7(12):e52935.
15. Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). *Br J Dermatol*. 2014;171(1):137-147.
16. Heller MM, Wong JW, Nguyen TV, et al. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. *Dermatol Clin*. 2012;30(2):281-291, ix.
17. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol*. 2011;65(1):137-174.
18. American Academy of Dermatology. Position statement on the treatment of psoriatic patients. <https://www.aad.org/Forms/Policies/Uploads/PS/PS on Treatment of Psoriatic Patients.pdf>. 2013.
19. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. *Clinical Infect Dis*. 2004;38(9):1261-1265.
20. Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). *JAMA Dermatol*. 2015;151(9):961-969.

Focus on Managing Patients with Moderate-to-Severe Plaque Psoriasis

21. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2008;58(5):826-850.
22. Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. *J Am Acad Dermatol*. 2015;73(3):420-428.e421.
23. Apremilast prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206088s000lbl.pdf. 2014. Accessed August 31 2017.
24. Vaidya TS, Anderson KL, Feldman SR. Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity. *Dermatol Online J*. 2015;21(9).
25. Schmitt J, Rosumeck S, Thomaschewski G, Sporbeck B, Haufe E, Nast A. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. *Br J Dermatol*. 2014;170(2):274-303.
26. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. *J Am Acad Dermatol*. 2007;56(1):31.e1-15.
27. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. *JAMA Derm*. 2013;149(10):1180-1185.
28. Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: Unmet medical needs and stakeholder perspectives. *Am Health Drug Benefits*. 2016;9(9):504-513.
29. Anderson KL, Feldman SR. Reasons for treatment changes in patients with moderate to severe psoriasis. *J Cutan Med Surg*. 2015;19(4):361-366.
30. Boehncke W-H, Schön MP. Psoriasis. *Lancet*. 2015;386(9997):983-994.
31. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). *JEADV*. 2016;30(7):1148-1158.
32. Bartos S, Hill D, Feldman SR. Review of maintenance of response to psoriasis treatments. *J Dermatolog Treat*. 2016;27(4):293-297.
33. Levin EC, Gupta R, Brown G, Malakouti M, Koo J. Biologic fatigue in psoriasis. *J Dermatolog Treat*. 2014;25(1):78-82.
34. Menter A, Tying SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. *J Am Acad Dermatol*. 2008;58(1):106-115.
35. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. *N Engl J Med*. 2003;349(21):2014-2022.
36. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet*. 2008;371(9625):1665-1674.
37. Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. *PLOS ONE*. 2012;7(4):e33486.
38. Bartelds GM, Kriekaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. *JAMA*. 2011;305(14):1460-1468.

Focus on Managing Patients with Moderate-to-Severe Plaque Psoriasis

39. Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. *J Am Acad Dermatol*. 2017;76(1):60-69.e9.
40. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. *Lancet*. 2015;386(9993):541-551.
41. Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. *J Am Acad Dermatol*. 2017;76(3):418-431.
42. Brezinski E, Armstrong A. Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. *Semin Cutan Med Surg*. 2014;33(2):91-97.
43. Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. *J Am Acad Dermatol*. 2008;59(1):27-33.
44. Aslam I, Feldman SR. Practical strategies to improve patient adherence to treatment regimens. *South Med J*. 2015;108(6):325-331.
45. Anstey A, Edwards A. Shared decision making in dermatology: asking patients, 'What is important to you?'. *Br J Derm*. 2014;170(4):759-760.
46. Renzi C, Di Pietro C, Gisondi P, et al. Insufficient knowledge among psoriasis patients can represent a barrier to participation in decision-making. *Acta Derm Venereol*. 2006;86(6):528-534.
47. Nelson PA, Chew-Graham CA, Griffiths CE, Cordingley L, Team I. Recognition of need in health care consultations: a qualitative study of people with psoriasis. *Br J Derm*. 2013;168(2):354-361.
48. Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. *JEADV*. 2013;27(2):187-198.
49. Uhlenhake EE, Kurkowski D, Feldman SR. Conversations on psoriasis--what patients want and what physicians can provide: a qualitative look at patient and physician expectations. *J Dermatolog Treat*. 2010;21(1):6-12.
50. Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. *Br J Derm*. 2016;175(2):273-286.
51. Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE) [published online Decembr 19, 2016]. *JEADV*. 2017;31(3):507-517.
52. Vanderpuye-Orgle J, Zhao Y, Lu J, et al. Evaluating the economic burden of psoriasis in the United States. *J Am Acad Dermatol*. 2015;72(6):961-967.e965.
53. Chi CC, Wang SH. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle. *BioMed Res Int*. 2014;2014:862851.
54. Staidle JP DT, Feldman S. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. *Expert Opin Pharmacother*. 2011;12(13):2041-2054.
55. Thomas CL, Finlay AY. The 'handprint' approximates to 1% of the total body surface area whereas the 'palm minus the fingers' does not. *B J Dermatol*. 2007;157(5):1080-1081.
56. Bremner S, Van Voorhees AS, Hsu S, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol*. 2010;63(6):1058-1069.
57. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. *J Am Acad Dermatol*. 2013;69(5):729-735.
58. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. *J Hypertens*. 2013;31(3):433-442; discussion 442-433.

Focus on Managing Patients with Moderate-to-Severe Plaque Psoriasis

59. de Oliveira M de FSP, Rocha B de O, Duarte GV. Psoriasis: classical and emerging comorbidities(). *An Bras Dermatol*. 2015;90(1):9-20.
60. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: A systematic review and meta-analysis of observational studies. *J Am Heart Assoc*. 2013;2(2):e000062.
61. Lin VW, Ringold S, Devine EB. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A Bayesian network meta-analysis. *Arch Dermatol*. 2012;148(12):1403-1410.
62. Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. *J Am Acad Dermatol*. 2016;74(6):1057-1065 e1054.
63. van Cranenburgh OD, de Korte J, Sprangers MA, de Rie MA, Smets EM. Satisfaction with treatment among patients with psoriasis: a web-based survey study. *Br J Dermatol*. 2013;169(2):398-405.
64. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. *J Am Acad Dermatol*. 2015;73(3):400-409.
65. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab sustains good efficacy and favourable safety in moderate to severe psoriasis up to 3 years of treatment: Results from a double-blind extension study [published online June 5, 2017]. *Br J Dermatol*. 2017. doi: 10.1111/bjd.15706.
66. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favorable safety profile through 5 years of treatment in moderate to severe psoriasis. eposter P2223 presented at the 26th European Academy of Dermatology and Venereology Congress, Geneva, Switzerland, 13-17 September 2017.
67. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. *N Engl J Med*. 2016;375(4):345-356.
68. Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase 3 study [published online May 19, 2017]. *Br J Dermatol*. 2017;doi: 10.1111/bjd.15666.
69. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. *N Engl J Med*. 2015;373(14):1318-1328.
70. Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. *Br J Dermatol*. 2015 Oct;173(4):930-9
71. Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. *Br J Dermatol*. 2015;173(4):949-961.
72. Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. *Br J Dermatol*. 2016 Jun;174(6):1266-76.
73. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. *J Allergy Clin Immunol*. 2015; 136:116-124.